Brief: Elicera Therapeutics Q1 Operating Loss Widens To SEK 4.7 Mln
26/04/2022 07:21
April 26 (Reuters) - Elicera Therapeutics AB ELIC.ST :
* ELICERA THERAPEUTICS AB (PUBL) INTERIM REPORT 1 JANUARY -
31
MARCH 2022
* Q1 OPERATING PROFIT/LOSS TOTALED SEK -4,741,051
(-2,404,551)
* Q1 LOSS FOR PERIOD TOTALED SEK -4,754,615 (-2,404,489)
Source text for Eikon: ID:nWkrbNVZ9n
Further company coverage: ELIC.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Elicera Therapeutics AB
See all newsBrief: Nomination Committee Proposes Margareth Jorvid As Chair Of Elicera Board
Brief: Elicera Therapeutics Carries Out Rights Issue Of About SEK 73 Mln
Sweden's Elicera Therapeutics Q1 loss narrows, reports positive clinical progress
Brief: Elicera Therapeutics Q1 Operating Loss SEK 5.1 Mln
Brief: Elicera Therapeutics Gets Notice Of Allowance For Japanease Patent